Rapport Therapeutics, Inc. (RAPP)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $22.50
- As of
Kresmion compiles this page from RAPP's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Rapport Therapeutics, Inc. (RAPP): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-20.
See the full RAPP dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RAPP on one page. Preview it with sample data, then open it live with a free account.
Preview the RAPP dossierActive events for RAPP
- mediumEarnings below estimates
Q2-2026: Missed consensus by 22.3%, EPS $-1.19 vs $-0.9733 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +388% to RAPP (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 52% of RAPP (2026Q2)
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +58% to RAPP (2026Q1)
- high13F: large reduction
RENAISSANCE TECHNOLOGIES LLC cut 92% of RAPP (2026Q1)
FREE, NO ACCOUNT
Every event on RAPP, as it fires
You are seeing 5 of 8 events recorded on RAPP since 2026-06-03.
The five above landed across 3 days. The other 3 were recorded on 1 other days. 4 of the 8 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RAPP (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 75383L102 · 2026Q2 | $9M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 75383L102 · 2026Q2 | $6.5M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 75383L102 · 2026Q2 | $3.4M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 75383L102 · 2026Q2 | $1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RAPP
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
RAPP against its peers
RAPP's return on equity of -23.0% ranks in the 74th percentile of 16 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | RAPP | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 77.3M | n/a | 8 |
| Operating margin | n/a | -354.4% | n/a | 8 |
| Net margin | n/a | -421.6% | n/a | 8 |
| Return on equity | -23.0% | -54.0% | 74 | 16 |
Peers (19): INBX, JANX, IMTX, MNKD, ORIC, SGP, MLTX, SVRA, AVBP, VOR, SLN, DRTS, JBIO, GLUE, SNDX, VSTM, LBRX, CGEM, RIGL. Left out: SPTX (no annual filing), CTY (no annual filing), AVLN (no annual filing), LTGO (no annual filing), KARD (no annual filing), LYCA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (RAPP: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow RAPP on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to RAPP for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.